Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Nov 8;12(1):113.
doi: 10.1186/s13045-019-0819-1.

CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

Delong Liu  1   2
Affiliations
Editorial

CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

Delong Liu. J Hematol Oncol. .

Abstract

New advances in the design and manufacture of monoclonal antibodies, bispecific T cell engagers, and antibody-drug conjugates make the antibody-directed agents more powerful with less toxicities. Small molecule inhibitors are routinely used now as oral targeted agents for multiple cancers. The discoveries of PD1 and PD-L1 as negative immune checkpoints for T cells have led to the revolution of modern cancer immunotherapy. Multiple agents targeting PD1, PD-L1, or CTLA-4 are widely applied as immune checkpoint inhibitors (ICIs) which alleviate the suppression of immune regulatory machineries and lead to immunoablation of once highly refractory cancers such as stage IV lung cancer. Tisagenlecleucel and axicabtagene ciloleucel are the two approved CD19-targeted chimeric antigen receptor (CAR) T cell products. Several CAR-T cell platforms targeting B cell maturation antigen (BCMA) are under active clinical trials for refractory and/or relapsed multiple myeloma. Still more targets such as CLL-1, EGFR, NKG2D and mesothelin are being directed in CAR-T cell trials for leukemia and solid tumors. Increasing numbers of novel agents are being studied to target cancer-intrinsic oncogenic pathways as well as immune checkpoints. One such an example is targeting CD47 on macrophages which represents a "do-not-eat-me" immune checkpoint. Fueling the current excitement of cancer medicine includes also TCR- T cells, TCR-like antibodies, cancer vaccines and oncolytic viruses.

Keywords: CAR-T; Cancer immunotherapy; Immune checkpoint inhibitor; TCR-T.

PubMed Disclaimer

Conflict of interest statement

DL serves on the speaker bureaus for Astellas, Incyte, and Janssen /Pharmacyclics. No pharmaceutical company was involved in this manuscript.

References

    1. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110. doi: 10.1056/NEJMoa1313984. - DOI - PubMed
    1. Maury Sébastien, Chevret Sylvie, Thomas Xavier, Heim Dominik, Leguay Thibaut, Huguet Françoise, Chevallier Patrice, Hunault Mathilde, Boissel Nicolas, Escoffre-Barbe Martine, Hess Urs, Vey Norbert, Pignon Jean-Michel, Braun Thorsten, Marolleau Jean-Pierre, Cahn Jean-Yves, Chalandon Yves, Lhéritier Véronique, Beldjord Kheira, Béné Marie C., Ifrah Norbert, Dombret Hervé. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine. 2016;375(11):1044–1053. doi: 10.1056/NEJMoa1605085. - DOI - PubMed
    1. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J. Adjuvant Trastuzumab in HER2-positive breast Cancer. N Engl J Med. 2011;365(14):1273–1283. doi: 10.1056/NEJMoa0910383. - DOI - PMC - PubMed
    1. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K. Trastuzumab Emtansine for HER2-positive advanced breast Cancer. N Engl J Med. 2012;367(19):1783–1791. doi: 10.1056/NEJMoa1209124. - DOI - PMC - PubMed
    1. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WSME, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA. Osimertinib or platinum–Pemetrexed in EGFR T790M–positive lung Cancer. N Engl J Med. 2016;376(7):629–640. doi: 10.1056/NEJMoa1612674. - DOI - PMC - PubMed

Publication types

Substances